{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:53:09Z","timestamp":1795042389842,"version":"4.10.2"},"reference-count":41,"publisher":"Georg Thieme Verlag KG","issue":"CP","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"crossref","award":["R-969613"],"award-info":[{"award-number":["R-969613"]}],"id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"crossref","award":["FAI-2022-0885"],"award-info":[{"award-number":["FAI-2022-0885"]}],"id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ALF-agreement","award":["FoUI-986927"],"award-info":[{"award-number":["FoUI-986927"]}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"crossref","award":["20220645"],"award-info":[{"award-number":["20220645"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TH Open"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recurrent thrombosis poses a clinical challenge in patients with antiphospholipid syndrome (APS). There are limited data on risk factors due to its rarity.<\/jats:p><jats:p>This study aimed to study the association between cardiovascular (CV) and APS-related risk factors and recurrent thrombosis and evaluate the adjusted Global Anti-Phospholipid Syndrome Score (aGAPSS).<\/jats:p><jats:p>This retrospective cohort study comprised APS patients at Karolinska University Hospital, Sweden, from 2014 to 2020 with follow-up until the last medical visit or death. Multiple thrombotic events per patient were included. Cox proportional hazard model estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Logistic regression and Poisson regression were conducted to further examine the relation between risk factors and recurrent thrombosis.<\/jats:p><jats:p>The cohort included 250 patients (67% women and 62% primary APS) with a median age of 44.5 (35\u201359) years. Forty-nine recurrent thrombotic events occurred in 36 patients, yielding an incidence of 4.46 (95% CI 3.30\u20135.90) per 100 person-years. Thrombocytopenia was associated with recurrent thrombosis (HR 2.57 [95% CI 1.01\u20136.02]). Although CV risk factors were not consistently significant for recurrent thrombosis, chronic kidney disease (CKD) indicated an increased probability (OR 2.55 [95% CI 1.01\u20136.26]). For each point of aGAPSS, the HR for recurrent thrombosis increased by 10% (1.10 [95% CI 1.01\u20131.19]). Notably, inadequate anticoagulation triggered recurrence in almost a quarter of cases.<\/jats:p><jats:p>Thrombocytopenia was confirmed as a major risk factor for recurrent thrombosis. CKD warrants closer attention in future assessment. Although an increase in aGAPSS was associated with recurrent thrombosis, further evaluation is required. Improving anticoagulation treatment is essential to reduce recurrence.<\/jats:p>","DOI":"10.1055\/a-2646-9016","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:46:27Z","timestamp":1751485587000},"source":"Crossref","is-referenced-by-count":3,"special_numbering":"S","title":["Risk Factors for Recurrent Thrombosis in Patients with Antiphospholipid Syndrome\u2014A Single-Centre Cohort Study"],"prefix":"10.1055","volume":"09","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-2610-7968","authenticated-orcid":false,"given":"Natali","family":"Karandyszowska","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Faustini","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hevgin","family":"Alag\u00fcnd\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Widaeus","sequence":"additional","affiliation":[{"name":"Department of Medicine, Danderyd Hospital, Stockholm, Sweden"},{"name":"Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia","family":"Carlens","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"},{"name":"School of Medical Sciences, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Louise","family":"Jensen","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Oksanen","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute of Environmental Medicine, Karolinska Institutet, Solna, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Magnusson","sequence":"additional","affiliation":[{"name":"Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden"},{"name":"Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iva","family":"Gunnarsson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3396-3244","authenticated-orcid":false,"given":"Elisabet","family":"Svenungsson","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Antovic","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bruzelius","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Hematology, Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"V Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11926-021-01008-8","article-title":"Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-year update","volume":"23","author":"D Erkan","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature","volume":"65","author":"L Andreoli","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients","volume":"74","author":"R Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"06","key":"ref5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.thromres.2015.10.029","article-title":"Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response","volume":"136","author":"SdaS Saraiva","year":"2015","journal-title":"Thromb Res"},{"issue":"03","key":"ref6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11926-013-0405-4","article-title":"Management of recurrent thrombosis in antiphospholipid syndrome","volume":"16","author":"C Nalli","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"M G Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijcard.2017.02.155","article-title":"The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction","volume":"240","author":"M Radin","year":"2017","journal-title":"Int J Cardiol"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.55563\/clinexprheumatol\/9royri","article-title":"Gender differences in primary antiphospholipid syndrome with vascular manifestations in 433 patients from four European centres","volume":"40 Suppl 134","author":"L Moschetti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3389\/fmed.2019.00211","article-title":"IgG anti-high-density lipoproteins antibodies discriminate between arterial and venous events in thrombotic antiphospholipid syndrome patients","volume":"6","author":"S Sciascia","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"08","key":"ref11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/kes388","article-title":"GAPSS: the Global Anti-Phospholipid Syndrome Score","volume":"52","author":"S Sciascia","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","article-title":"The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort","volume":"49","author":"M Radin","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"04","key":"ref13","doi-asserted-by":"crossref","first-page":"101893","DOI":"10.1016\/j.berh.2023.101893","article-title":"Systemic lupus erythematosus and damage: What has changed over the past 20 years?","volume":"37","author":"C Mu\u00f1oz-Grajales","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"04","key":"ref14","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5152\/eurjrheum.2020.20099","article-title":"Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome","volume":"7","author":"A Yaz\u0131c\u0131","year":"2020","journal-title":"Eur J Rheumatol"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-014-0494-8","article-title":"The significance and management of thrombocytopenia in antiphospholipid syndrome","volume":"17","author":"B Artim-Esen","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/biomedicines9091170","article-title":"Immune thrombocytopenia in antiphospholipid syndrome: Is it primary or secondary?","volume":"9","author":"R Tomasello","year":"2021","journal-title":"Biomedicines"},{"issue":"01","key":"ref17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/rheumatology\/keac264","article-title":"Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications","volume":"62","author":"Y Shi","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"S Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref19","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jth.14261","article-title":"Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-\u03b22 glycoprotein I antibody detection assays","volume":"16","author":"W Chayoua","year":"2018","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cca.2013.11.009","article-title":"Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies","volume":"428","author":"R Forastiero","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"K MJ Devreese","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"M Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1177\/0961203317703493","article-title":"Independent validation of the adjusted GAPSS: Role of thrombotic risk assessment in the real-life setting","volume":"26","author":"N Fernandez Mosteirin","year":"2017","journal-title":"Lupus"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12016-021-08915-9","article-title":"Does Adjusted Global Antiphospholipid Syndrome Score (aGAPSS) predict the obstetric outcome in antiphospholipid antibody carriers? A single-center study","volume":"63","author":"S Del Barrio-Longarela","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"09","key":"ref25","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1515\/cclm-2024-0114","article-title":"Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: Clinical characteristics, antibody profiles and estimate of the risk of recurrence","volume":"62","author":"V Pengo","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"e003601","DOI":"10.1136\/rmdopen-2023-003601","article-title":"Cardiovascular risk assessment in patients with antiphospholipid syndrome: a cross-sectional performance analysis of nine clinical risk prediction tools","volume":"9","author":"G C Drosos","year":"2023","journal-title":"RMD Open"},{"issue":"08","key":"ref27","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/art.21968","article-title":"Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V","volume":"54","author":"T Shi","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11684-015-0426-7","article-title":"Anti-\u03b22 glycoprotein I antibodies in complex with \u03b22 glycoprotein I induce platelet activation via two receptors: apolipoprotein E receptor 2\u2032 and glycoprotein I b\u03b1","volume":"10","author":"W Zhang","year":"2016","journal-title":"Front Med"},{"issue":"03","key":"ref29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/keab475","article-title":"Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study","volume":"61","author":"J Pardos-Gea","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"03","key":"ref30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/rheumatology\/kez596","article-title":"Identifying phenotypes of patients with antiphospholipid antibodies: results from a cluster analysis in a large cohort of patients","volume":"60","author":"S Sciascia","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2020.01.017","article-title":"Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?","volume":"74","author":"C M Yelnik","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12016-021-08862-5","article-title":"Risk factors for the development of the disease in antiphospholipid antibodies carriers: A long-term follow-up study","volume":"62","author":"R D Pablo","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jth.13763","article-title":"Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: A longitudinal study","volume":"15","author":"R Hisada","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejim.2020.10.011","article-title":"Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia","volume":"84","author":"T Moulinet","year":"2021","journal-title":"Eur J Intern Med"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.3390\/cells10123386","article-title":"Platelet activation mechanisms and consequences of immune thrombocytopenia","volume":"10","author":"S Sun","year":"2021","journal-title":"Cells"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fimmu.2018.01008","article-title":"Renal involvement in antiphospholipid syndrome","volume":"9","author":"A Turrent-Carriles","year":"2018","journal-title":"Front Immunol"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12959-022-00409-8","article-title":"The trends in the incidence and thrombosis-related comorbidities of antiphospholipid syndrome: A 14-year nationwide population-based study","volume":"20","author":"W C Yao","year":"2022","journal-title":"Thromb J"},{"issue":"01","key":"ref38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-015-0614-5","article-title":"Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: An observational cross-sectional study with longitudinal follow-up","volume":"17","author":"J Gerhardsson","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"02","key":"ref39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/jth.15158","article-title":"Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure","volume":"19","author":"V Pengo","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1160\/TH04-11-0723","article-title":"Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia","volume":"93","author":"P R Ames","year":"2005","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar3759","article-title":"Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study","volume":"14","author":"J T Gustafsson","year":"2012","journal-title":"Arthritis Res Ther"}],"container-title":["TH Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2646-9016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:24:52Z","timestamp":1754004292000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2646-9016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":41,"journal-issue":{"issue":"CP","published-online":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025]]}},"alternative-id":["a26469016"],"URL":"https:\/\/doi.org\/10.1055\/a-2646-9016","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2512-9465"],"issn-type":[{"value":"2512-9465","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,2]]},"published":{"date-parts":[[2025,7,2]]}}}